We observed that there was a significantly lower burden of residual disease across RCB categories in the phenocopy group compared to the not phenocopy group (Cochran-Armitage P = 0.0101, Fig. 5A), consistent with a continuous association of TP53-loss phenocopy status with magnitude of chemotherapy response, at least in triple negative breast cancer. Here, TP53 is linked to triple-negative breast carcinoma.